Read as much as you want on, anywhere and anytime, for just 99¢.

FDA expands use of J&J cancer drug

WASHINGTON — The Food and Drug Administration on Monday expanded its approval­ of Johnson & Johnson’s prostate cancer pill, Zytiga, for men with an earlier stage of the disease.

The agency said Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group.

Continue reading below

The FDA had in April 2011 approved the drug for men with prostate cancer who have already taken the chemotherapy drug docetaxel.

Zytiga works by decreasing the male hormone testosterone. Testosterone stimulates the growth of prostate tumors, and treatment often includes administering drugs aimed at cutting the body’s testosterone production.

In a study, the typical patient taking Zytiga survived five months longer than the typical patient taking a fake pill, or placebo.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of